Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.00    -1.25 (-13.51%)
Bid:
7.50
Ask:
8.50
Spread: 1.00 (13.333%)
Market Cap: £17.52m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Investor presentation

26 Aug 2020 11:55

RNS Number : 2263X
IXICO plc
26 August 2020
 

IXICO plc

("IXICO" or the "Company")

 

Investor presentation

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that a recording of the online Company presentation, delivered by Giulio Cerroni, Chief Executive Officer, and Grant Nash, Chief Finance Officer, on Tuesday 25 August, surrounding the Company's recent trading update, is now available to watch back on the Investor Meet Company platform. The Q&A has also been published following the meeting.

Investors can sign up to Investor Meet Company for free and add to meet IXICO plc via the following link, which will take you to the recording of the presentation and the Q&A: https://www.investormeetcompany.com/ixico-plc/register-investor

No new price-sensitive information is disclosed as part of the presentation.

 

For further information please contact:

 

IXICO plc

+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

 

 

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0)20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

 

Michael F Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or IXICO@walbrookpr.com

 

Paul McManus / Lianne Cawthorne /

Mob: 07980 541 893 / 07584 391 303 /

Alice Woodings

07407 804 654

     

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.

 

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

 

More information is available on www.IXICO.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
END
 
 
NRAPFMMTMTITBLM
Date   Source Headline
12th Nov 20093:59 pmRNSBlocklisting Interim Review
4th Nov 20091:36 pmRNSHolding(s) in Company
23rd Oct 20099:42 amRNSHolding(s) in Company
14th Oct 20097:00 amRNSResearch Update
18th Aug 20097:00 amRNSInterim Management Statement
23rd Jul 20097:00 amRNSRe Agreement
20th May 20097:00 amRNSInterim Results
11th May 200911:12 amRNSBlocklisting Interim Review
5th May 20099:14 amRNSCPT commits to the development of Cogane
20th Apr 20097:00 amRNSResearch Update
13th Mar 20099:58 amRNSResult of AGM
10th Mar 20095:16 pmRNSDirector/PDMR Shareholding
10th Mar 20095:13 pmRNSDirector/PDMR Shareholding
10th Mar 20095:13 pmRNSDirector/PDMR Shareholding
10th Mar 20095:10 pmRNSDirector/PDMR Shareholding
3rd Mar 20095:26 pmRNSAnnual Information Update
19th Feb 20093:42 pmRNSHolding(s) in Company
17th Feb 20094:00 pmRNSHolding(s) in Company
17th Feb 20097:00 amRNSInterim Management Statement
28th Jan 200910:48 amRNSAnnual Report & Accounts and Notice of AGM
19th Dec 20084:41 pmRNSSecond Price Monitoring Extn
19th Dec 20084:37 pmRNSPrice Monitoring Extension
12th Dec 200812:00 pmRNSPortfolio Update
27th Nov 20087:00 amRNSFinal Results
14th Nov 20081:00 pmRNSTrading Statement
13th Nov 20087:00 amRNSBoard Change
11th Nov 200810:09 amRNSDirector/PDMR Shareholding
5th Nov 20081:43 pmRNSBlocklisting Interim Review
9th Oct 20082:45 pmRNSDirector/PDMR Shareholding
10th Sep 20089:27 amRNSDirector/PDMR Shareholding
8th Aug 20083:21 pmRNSDirector/PDMR Shareholding
21st Jul 20084:35 pmRNSPrice Monitoring Extension
9th Jul 20084:40 pmRNSDirector/PDMR Shareholding
3rd Jul 20087:00 amRNSInterim Management Statement
13th Jun 200812:47 pmRNSDirector/PDMR Shareholding
11th Jun 20087:00 amRNSProduct Launch
4th Jun 20085:59 pmRNSTotal Voting Rights
3rd Jun 200810:06 amRNSDirector/PDMR Shareholding
3rd Jun 200810:04 amRNSDirector/PDMR Shareholding
29th May 20087:00 amRNSInterim Results
21st May 20087:00 amRNSMyogane granted European Unio
16th May 200811:32 amRNSNotice of Results
12th May 20082:10 pmRNSDirector/PDMR Shareholding
2nd May 200810:25 amRNSBlocklisting Interim Review
1st May 20089:32 amRNSTotal Voting Rights
14th Apr 200812:14 pmRNSDirector/PDMR Shareholding
14th Apr 200811:58 amRNSHolding(s) in Company
14th Apr 200811:48 amRNSHolding(s) in Company
9th Apr 200810:18 amRNSHolding(s) in Company
4th Apr 20086:08 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.